Trial NCT01690325

View at ClinicalTrials.gov 
Org. Study IDs: WSG-AM05

Last trial update was posted on 2018-08-13

MeSH Interventions

Bevacizumab Cyclophosphamide Docetaxel Epirubicin Trastuzumab

MeSH Conditions

Breast Neoplasms

Other Conditions

Breast Cancer

Stopping Reasons

Therapy of HER2+ patients according to protocol was no longer appropriate. Patient enrolment behind planned schedule and challenges of site performance

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID